Assertio Holdings faces a critical inflection point as its core specialty pharmaceutical portfolio experiences rapid erosion, evidenced by a 62.5% revenue decline in 2026Q1. The company's inability to align its fixed SG&A cost structure with this shrinking top...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 8, 2026 | -$2.93-53.4% vs -$1.91 | $10M+10.8% vs $9M |
Q2 2026 Mar 16, 2026 | -$1.86+39.0% vs -$3.05 | $14M+118.5% vs $6M |
Q4 2025 Nov 10, 2025 | $1.65+229.4% vs -$1.27 | $49M+83.0% vs $27M |
Q3 2025 Aug 11, 2025 | -$2.55-88.9% vs -$1.35 | $29M+4.4% vs $28M |
TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P.
Benchmark ASRT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Assertio Holdings, Inc. (ASRT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.50 | $151.86M | -4.96 | -5% | -25.59% | -28.25% | — | |
| $34.10 | $1.38B | 28.66 | 27.37% | 6.57% | 28.67% | — | |
| $19.33 | $6.17B | 87.86 | 8.05% | 5.05% | — | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $22.45 | $728.14M | 12.98 | 23.62% | 5.93% | 15.96% | — |
Assertio Holdings, Inc. (ASRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Assertio Holdings, Inc. (ASRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 16, 2026·SEC
May 18, 2026·SEC
May 13, 2026·SEC
Get notified when ASRT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Assertio Holdings, Inc. (ASRT) stock FAQ — growth, dividends, profitability & financials explained
Assertio Holdings, Inc. (ASRT) reported $102.2M in revenue for fiscal year 2025. This represents a 33952% increase from $0.3M in 1996.
Assertio Holdings, Inc. (ASRT) saw revenue decline by 5.0% over the past year.
Assertio Holdings, Inc. (ASRT) reported a net loss of $35.7M for fiscal year 2025.
Assertio Holdings, Inc. (ASRT) has a return on equity (ROE) of -28.3%. Negative ROE indicates the company is unprofitable.
Assertio Holdings, Inc. (ASRT) had negative free cash flow of $7.1M in fiscal year 2025, likely due to heavy capital investments.
